Мониторинг химеризма после трансплантации аллогенных гемопоэтических стволовых клеток
https://doi.org/10.23873/2074-0506-2022-14-4-488-499
Аннотация
Трансплантация аллогенных гемопоэтических стволовых клеток является одним из эффективных методов лечения пациентов с заболеваниями системы крови.
Среди главных показателей успешной трансплантации в таких случаях является установление полного (100%) донорского химеризма. Мониторинг химеризма позволяет оценить не только приживление трансплантата, но и потенциально спрогнозировать риск развития первичной/вторичной несостоятельности трансплантата, вероятность развития рецидива заболевания и реакции «трансплантат против хозяина».
Задачами данного обзора являются: 1) обобщение основных понятий, связанных с химеризмом после трансплантации аллогенных гемопоэтических стволовых клеток, и 2) рассмотрение вопроса о необходимости исследования химеризма в различных клеточных популяциях, а также взаимосвязи химеризма и развития различных иммунологических осложнений.
Об авторах
Д. С. Дубняк
ФГБУ «НМИЦ гематологии» МЗ РФ
Россия
Россия
Дарья Станиславовна Дубняк, врач-гематолог
125167, Москва, Новый Зыковский пр-д, д. 4
Н. В. Рисинская
ФГБУ «НМИЦ гематологии» МЗ РФ
Россия
Россия
Наталья Владимировна Рисинская, канд. биол. наук, старший научный сотрудник лаборатории молекулярной гематологии
125167, Москва, Новый Зыковский пр-д, д. 4
М. Ю. Дроков
ФГБУ «НМИЦ гематологии» МЗ РФ
Россия
Россия
Михаил Юрьевич Дроков, канд. мед. наук, врач-гематолог, руководитель сектора научных исследований химиотерапии гемобластозов, депрессий кроветворения и трансплантации костного мозга
125167, Москва, Новый Зыковский пр-д, д. 4
А. Б. Судариков
ФГБУ «НМИЦ гематологии» МЗ РФ
Россия
Россия
Андрей Борисович Судариков, д-р биол. наук, заведующий лабораторией молекулярной гематологии
125167, Москва, Новый Зыковский пр-д, д. 4
Список литературы
1. Owen RD. Immunogenetic consequences of vascular anastomoses between bovine twins. Science. 1945;102(2651):400–401. PMID: 17755278 https://doi.org/10.1126/science.102.2651.400
2. Anderson D, Billingham RE, Lampkin GH, Medawar PB. The use of skin grafting to distinguish between monozygotic and dizygotic twins in cattle. Heredity (Edinb). 1951;5(3):379–397. https://doi.org/10.1038/hdy.1951.38
3. Ford CE, Hamerton JL, Barnes DWH, Loutit JF. Cytological identification of radiation-chimæras. Nature. 1956;177(4506):452–454. PMID: 13309336 https://doi.org/10.1038/177452a0
4. Thomas ED, Lochte HL, Cannon JH, Sahler OD. Supralethal whole body irradiation and isologous marrow transplantation in man. J Clin Invest. 1959;38(10 Pt1-2):1709–1716. PMID: 13837954 https://doi.org/10.1172/JCI103949
5. Khan F, Agarwal A, Agrawal S. Significance of chimerism in hematopoietic stem cell transplantation: New variations on an old theme. Bone Marrow Transplantation. 2004;34(1):1–12. PMID: 15156163 https://doi.org/10.1038/sj.bmt.1704525
6. Clark JR, Scott SD, Jack AL, Lee H, Mason J, Carter GI, et al. Monitoring of chimerism following allogeneic haemato-poietic stem cell transplantation (HSCT): technical recommendations for the use of short tandem repeat (STR) based techniques, on behalf of the United Kingdom national external quality assessment service for leucocyte immunophenotyping chimerism working group. Br J Haematol. 2015;168(1):26–37. PMID: 25145701 https://doi.org/10.1111/bjh.13073
7. van Dijk BA, Drenthe-Schonk AM, Bloo A, Kunst VA, Janssen JT, Witte TJ. Erythrocyte repopulation after allogeneic bone marrow transplantation: analysis using erythrocyte antigens. Transplantation. 1987;44(5):650–654. PMID: 3318035 https://doi.org/10.1097/00007890198711000-00011
8. Hendriks EC, De Man AJ, Van Berkel YC, Stienstra S, Witte T. Flow cytometric method for the routine follow-up of red cell populations after bone marrow transplantation. Br J Haematol. 1997;97(1):141–145. PMID: 9136956 https://doi.org/10.1046/j.1365-2141.1997.d01-2138.x
9. Andreani M, Testi M, Battarra M, Lucarelli G. Split chimerism between nucleated and red blood cells after bone marrow transplantation for haemoglobinopathies. Chimerism. 2011;2(1):21–22. PMID: 21547033 https://doi.org/10.4161/chim.15057
10. Buño I, Nava P, Simón A, GonzálezRivera M, Jiménez JL, Balsalobre P, et al. A comparison of fluorescent in situ hybridization and multiplex short tandem repeat polymerase chain reaction for quantifying chimerism after stem cell transplantation. Haematologica. 2005;90(10):1373–1379. PMID: 16219574
11. Alizadeh M, Bernard M, Danic B, Dauriac C, Birebent B, Lapart C, et al. Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood. 2002;99(12):4618–4625. PMID: 12036896 https://doi.org/10.1182/blood.v99.12.4618
12. Jółkowska J, Pieczonka A, Strabel T, Boruczkowski D, Wachowiak J, Bader P, et al. Hematopoietic chimerism after allogeneic stem cell transplantation: a comparison of quantitative analysis by automated DNA sizing and fluorescent in situ hybridization. BMC Blood Disord. 2005;5(1):1. PMID: 15642114 https://doi. org/10.1186/1471-2326-5-1
13. Dewald G, Stallard R, Saadi AA, Arnold S, Bader PI, Blough R, et al. A multicenter investigation with interphase fluorescence in situ hybridization using Xand Y-chromosome probes. Am J Med Genet. 1998;76(4):318–326. PMID: 9545096
14. Thiede C, Bornhäuser M, Ehninger G. Strategies and clinical implications of chimerism diagnostics after allogeneic hematopoietic stem cell transplantation. Acta Haematologica. 2004;112(1– 2):16–23. PMID: 15179000 https://doi.org/10.1159/000077555
15. Kristt D, Stein J, Yaniv I, Klein T. Assessing quantitative chimerism longitudinally: technical considerations, clinical applications and routine feasibility. Bone Marrow Transplant. 2007;39(5):255–268. PMID: 17262064 https://doi.org/10.1038/sj.bmt.1705576
16. Andrikovics H, Őrfi Z, Meggyesi N, Bors A, Varga L, Kövy P, et al. Current trends in applications of circulatory microchimerism detection in transplantation. Int J Mol Sci. 2019;20(18):4450. PMID: 31509957 https://doi.org/10.3390/ijms20184450
17. Bach C, Tomova E, Goldmann K, Weisbach V, Roesler W, Mackensen A, et al. Monitoring of hematopoietic chimerism by real-time quantitative PCR of micro insertions/deletions in samples with low DNA quantities. Transfus Med Hemother. 2015;42(1):38–45. PMID: 25960714 https://doi.org/10.1159/000370255
18. Fan H, Chu JY. A brief review of short tandem repeat mutation. Genomics, Proteomics Bioinformatics. 2007;5(1):7–14. PMID: 17572359 https://doi.org/10.1016/S1672-0229(07)60009-6
19. Nollet F, Billiet J, Selleslag D, Criel A. Standardisation of multiplex fluorescent short tandem repeat analysis for chimerism testing. Bone Marrow Transplant. 2001;28(5):511–518. PMID: 11593326 https://doi.org/10.1038/sj.bmt.1703162
20. Blouin AG, Ye F, Williams J, Askar M. A practical guide to chimerism analysis: review of the literature and testing practices worldwide. Hum Immunol. 2021;82(11):838–849. PMID: 34404545 https://doi.org/10.1016/j.humimm.2021.07.013
21. Stahl T, Böhme MU, Kröger N, Fehse B. Digital PCR to assess hematopoietic chimerism after allogeneic stem cell transplantation. Exp Hematol. 2015;43(6):462–468.e1. PMID: 25795523 https://doi.org/10.1016/j.exph.2015.02.006
22. Kletzel M, Huang W, Olszewski M, Khan S. Validation of chimerism in pediatric recipients of allogeneic hematopoietic stem cell transplantation (HSCT) a comparison between two methods: realtime PCR (qPCR) vs. variable number tandem repeats PCR (VNTR PCR). Chimerism. 2013;4(1):1–8. PMID: 23238335 https://doi.org/10.4161/chim.23158
23. Quan PL, Sauzade M, Brouzes E. DPCR: a technology review. Sensors (Switzerland). 2018;18(4):1271. PMID: 29677144 https://doi.org/10.3390/s18041271
24. Basu AS. Digital assays part I: partitioning statistics and digital PCR. SLAS Technology. 2017;22(4):369–386. PMID: 28448765 https://doi.org/10.1177/2472630317705680
25. Das TP, Kipp DA, Kliman DS, Patil SS, Curtis DJ, O'Brien ME, et al. Important factors in implementation of lineage-specific chimerism analysis for routine use. Bone Marrow Transplantat. 2021;56(4):946–948. PMID: 33082555 https://doi.org/10.1038/s41409-02001089-6
26. Bader P. Documentation of engraftment and chimerism after HSCT. Chapter 20. In: Carreras E, Dufour C, Mohty M, Kröger N. The EBMT handbook: hematopoietic stem cell transplantation and cellular therapies. 7th edition. Cham (CH): Springer; 2019. p. 143–147. https://doi.org/10.1007/978-3-030-02278-5_20
27. Sellmann L, Rabe K, Bünting I, Dammann E, Göhring G, Ganser A, et al. Diagnostic value of highly-sensitive chimerism analysis after allogeneic stem cell transplantation. Bone Marrow Transplant. 2018;53(11):1457–1465. PMID: 29720704 https://doi.org/10.1038/s41409-018-0176-7
28. Miura Y, Tanaka J, Toubai T, Tsutsumi Y, Kato N, Hirate D, et al. Analysis of donor-type chimerism in lineage-specific cell populations after allogeneic myeloablative and nonmyeloablative stem cell transplantation. Bone Marrow Transplant. 2006;37(9):837–843. PMID: 16547484 https://doi.org/10.1038/sj.bmt.1705352
29. Gineikiene E, Stoskus M, Griskevicius L. Recent advances in quantitative chimerism analysis. Expert Rev Mol Diagn. 2009;9(8):817–832. PMID: 19895227 https://doi.org/10.1586/erm.09.66
30. Lawler M, McCann SR, Marsh JCW, Ljungman P, Hows J, Vandenberghe E, et al. Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA. Br J Haematol. 2009;144(6):933–945. PMID: 19183198 https://doi.org/10.1111/j.13652141.2008.07533.x
31. Zimmerman C, Shenoy S. Chimerism in the realm of hematopoietic stem cell transplantation for non-malignant disorders – a perspective. Front Immunol. 2020;11:1791. PMID: 32903736 https://doi.org/10.3389/fimmu.2020.01791
32. Navarro-Bailón A, Carbonell D, Escudero A, Chicano M, Muñiz P, SuárezGonzález J, et al. Short tandem repeats (STRS) as biomarkers for the quantitative follow-up of chimerism after stem cell transplantation: methodological considerations and clinical application. Genes (Basel). 2020;11(9):993. PMID: 32854376 https://doi.org/10.3390/genes11090993
33. Stumph J, Vnencak-Jones CL, Koyama T, Frangoul H. Comparison of peripheral blood and bone marrow samples for detection of post transplant mixed chimerism. Bone Marrow Transplant. 2008;41(6):589–590. PMID: 18037938 https://doi.org/10.1038/sj.bmt.1705938
34. Rauwerdink CA, Tsongalis GJ, Tosteson TD, Hill JM, Meehan KR. The practical application of chimerism analyses in allogeneic stem cell transplant recipients: blood chimerism is equivalent to marrow chimerism. Exp Mol Pathol. 2012;93(3):339–344. PMID: 22850633 https://doi.org/10.1016/j.yexmp.2012.07.003
35. Bach C, Steffen M, Roesler W, Winkler J, Mackensen A, Stachel K-D, et al. Systematic comparison of donor chimerism in peripheral blood and bone marrow after hematopoietic stem cell transplantation. Blood Cancer J. 2017;7(6):e566. PMID: 28574489 https://doi.org/10.1038/bcj.2017.42
36. Reshef R, Hexner EO, Loren AW, Frey NV, Stadtmauer EA, Luger SM, et al. Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reducedintensity conditioning. Biol Blood Marrow Transplant. 2014;20(11):1758– 1766. PMID: 25016197 https://doi.org/10.1016/j.bbmt.2014.07.003
37. Jain T, Kunze KL, Mountjoy L, Partain DK, Kosiorek H, Khera N, et al. Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis. Blood Cancer J. 2020;10(3):36. PMID: 32157091 https://doi.org/10.1038/s41408-020-0302-9
38. Блау О.В. Химеризм после аллогенной трансплантации гемопоэтических стволовых клеток. Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2013;6(1):34–39.
39. Lamba R, Abella E, Kukuruga D, Klein J, Savasan S, Abidi MH, et al. Mixed hematopoietic chimerism at day 90 following allogenic myeloablative stem cell transplantation is a predictor of relapse and survival. Leukemia. 2004;18(10):1681–1686. PMID: 15318247 https://doi.org/10.1038/sj.leu.2403468
40. Koreth J, Kim HT, Nikiforow S, Milford EL, Armand P, Cutler C, et al. Donor chimerism early after reducedintensity conditioning hematopoietic stem cell transplantation predicts relapse and survival. Biol Blood Marrow Transplant. 2014;20(10):1516–1521. PMID: 24907627 https://doi.org/10.1016/j.bbmt.2014.05.025
41. Bacher U, Haferlach T, Fehse B, Schnittger S, Kröger N. Minimal residual disease diagnostics and chimerism in the post-transplant period in acute myeloid leukemia. Scientific World Journal. 2011;11:310–319. PMID: 21298222 https://doi.org/10.1100/tsw.2011.16
42. Mountjoy L, Palmer J, Kunze KL, Khera N, Sproat LZ, Leis JF, et al. Does early chimerism testing predict outcomes after allogeneic hematopoietic stem cell transplantation? Leuk Lymphoma. 2021;62(1):252–254. PMID: 33012186 https://doi.org/10.1080/10428194.2020.1827249
43. Deeg HJ, Salit RB, Monahan T, Schoch G, McFarland C, Scott BL, et al. Early mixed lymphoid donor/host chimerism is associated with improved transplant outcome in patients with primary or secondary myelofibrosis: mixed chimerism, GVHD, and relapse. Biol Blood Marrow Transplant. 2020;26(12):2197–2203. PMID: 32693211 https://doi.org/10.1016/j.bbmt.2020.07.013
44. Breuer S, Preuner S, Fritsch G, Daxberger H, Koenig M, Poetschger U, et al. Early recipient chimerism testing in the Tand NK-cell lineages for risk assessment of graft rejection in pediatric patients undergoing allogeneic stem cell transplantation. Leukemia. 2012;26(3):509–519. PMID: 21926962 https://doi.org/10.1038/leu.2011.244
45. Baron F, Baker JE, Storb R, Gooley TA, Sandmaier BM, Maris MB, et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood. 2004;104(8):2254–2262. PMID:15226174 https://doi.org/10.1182/blood-2004-04-1506
46. Bornhäuser M, Thiede C, Platzbecker U, Jenke A, Helwig A, Plettig R, et al. Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients. Clin Cancer Res. 2001;7(8):2254–2262. PMID: 11489799
47. Rosenow F, Berkemeier A, Krug U, Müller-Tidow C, Gerss J, Silling G, et al. CD34+ lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT. Bone Marrow Transplant. 2013;48(8):1070–1076. PMID: 23376821 https://doi.org/10.1038/bmt.2013.2
48. Jiang Y, Wan L, Qin Y, Wang X, Yan S, Xie K, et al. Donor chimerism of B cells and nature killer cells provides useful information to predict hematologic relapse following allogeneic hematopoietic stem cell transplantation. PLoS One. 2015;10(7):e0133671. PMID: 26226104 https://doi.org/10.1371/journal.pone.0133671
49. Yang Y-N, Wang X, Qin Y, Wan L, Jiang Y, Wang C. Is there a role for B lymphocyte chimerism in the monitoring of B-acute lymphoblastic leukemia patients receiving allogeneic stem cell transplantation? Chronic Dis Transl Med. 2015;1(1):48–54. PMID: 29062987 https://doi.org/10.1016/j.cdtm.2015.02.004
50. Hsieh MM, Fitzhugh CD, Tisdale JF. Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now. Blood. 2011;118(5):1197– 1207. PMID: 21628400 https://doi. org/10.1182/blood-2011-01-332510
51. Bornhäuser M, Oelschlaegel U, Platzbecker U, Bug G, Lutterbeck K, Kiehl MG, et al. Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation. Haematologica. 2009;94(11):1613–1617. PMID: 19880783 https://doi.org/10.3324/haematol.2009.007765
52. Broglie L, Helenowski I, Jennings LJ, Schafernak K, Duerst R, Schneiderman J, et al. Early mixed T-cell chimerism is predictive of pediatric AML or MDS relapse after hematopoietic stem cell transplant. Pediatr Blood Cancer. 2017;64(9):e26493. PMID: 28266766 https://doi.org/10.1002/pbc.26493
53. Lee HC, Saliba RM, Rondon G, Chen J, Charafeddine Y, Medeiros LJ, et al. Mixed T lymphocyte chimerism after allogeneic hematopoietic transplantation is predictive for relapse of acute myeloid leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant. 2015;21(11):1948–1954. PMID: 26183077 https://doi.org/10.1016/j.bbmt.2015.07.005
54. El-Cheikh J, Vazquez A, Crocchiolo R, Furst S, Calmels B, Castagna L, et al. Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. Am J Hematol. 2012;87(12):1074–1078. PMID: 22911907 https://doi.org/10.1002/ajh.23319
55. Mattsson J, Uzunel M, Remberger M, Ringdén O. T cell mixed chimerism is significantly correlated to a decreased risk of acute graft-versus-host disease after allogeneic stem cell transplantation. Transplantation. 2001;71(3):433–439. PMID: 11233907 https://doi.org/10.1097/00007890-200102150-00017
56. Baron F, Little MT, Storb R. Kinetics of engraftment following allogeneic hematopoietic cell transplantation with reduced-intensity or nonmyeloablative conditioning. Blood Rev. 2005;19(3):153–164. PMID: 15748963 https://doi.org/10.1016/j.blre.2004.06.003
57. Antin JH, Childs R, Filipovich AH, Giralt S, Mackinnon S, Spitzer T, et al. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2001;7(9):473–485. PMID: 11669214 https://doi.org/10.1053/bbmt.2001.v7.pm11669214
58. Zvyagin IV, Mamedov IZ, Tatarinova OV, Komech EA, Kurnikova EE, Boyakova EV, et al. Tracking T-cell immune reconstitution after TCR/ CD19-depleted hematopoietic cells transplantation in children. Leukemia. 2017;31(5):1145–1153. PMID: 27811849 https://doi.org/10.1038/leu.2016.321
59. Попова Н.Н., Савченко В.Г. Реконституция Т-клеточного звена иммунной системы у больных после трансплантации аллогенных гемопоэтических стволовых клеток. Гематология и трансфузиология. 2020;65(1):24–38.
60. Михальцова Е.Д., Попова Н.Н., Дроков М.Ю., Капранов Н.М., Давыдова Ю.О., Васильева В.А. и др. Влияние режимов профилактики РТПХ на восстановление клеточного звена иммунной системы у пациентов после трансплантации аллогенных гемопоэтических стволовых клеток. Медицинская иммунология. 2021;23(5):1125–1136.https://doi.org/10.15789/1563-0625-IOG-2167
Рецензия
Для цитирования:
Дубняк Д.С., Рисинская Н.В., Дроков М.Ю., Судариков А.Б. Мониторинг химеризма после трансплантации аллогенных гемопоэтических стволовых клеток. Трансплантология. 2022;14(4):488-499. https://doi.org/10.23873/2074-0506-2022-14-4-488-499
For citation:
Dubnyak D.S., Risinskaya N.V., Drokov M.Yu., Sudarikov A.B. Monitoring of chimerism after allogeneic hematopoietic stem cell transplantation. Transplantologiya. The Russian Journal of Transplantation. 2022;14(4):488-499. https://doi.org/10.23873/2074-0506-2022-14-4-488-499
Просмотров:
1076
Послать статью по эл. почте 